Document Type : Original Article(s)
Authors
- Maryam Kasraeian 1
- Mehdi Dianatpour 2
- Marzie Zare 1
- Marjan Zare 3
- Azam Faraji 1
- Homeira Vafaei 1
- Nasrin Asadi 1
- Khadije Bazrafshan 4
1 Maternal-Fetal Medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 Department of Public Health, Khalkhal University of Medical Sciences, Khalkhal, Iran
4 Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
Background: Efforts to improve prenatal diagnosis of Down syndrome have been made, with amniocentesis representing an invasive procedure, and maternal serum biochemical markers are among the non-invasive options. This study aimed to examine the association between serum biochemical marker values and amniocentesis results in the prenatal diagnostics of Down syndrome in early pregnancy.
Methods: In a cross-sectional study, data from pregnant women in the first trimester undergoing amniocentesis test for the diagnosis of fetal genetic diseases were collected during 2021-2022. Maternal weight, maternal age, gestational age at nuchal translucency (NT) scan, nasal bone (NB) status, and serum chemical biomarkers—including pregnancy-associated plasma protein-A (PAPP-A), and beta-human chorionic gonadotropins (β-hCG) were assessed.
Results: Of 1,987 amniocentesis cases, 96.5% were normal, and 3.5% were abnormal. Down syndrome was present in approximately 3% of cases. Maternal weight was significantly lower in the abnormal amniocentesis group than in the normal group. After adjusting for maternal weight, maternal age, NT, and β-hCG were significantly higher in the abnormal amniocentesis group, whereas PAPP-A was lower. The NB status did not differ between groups. A PAPP-A level of <0.42 multiple of median (MoM) (sensitivity=90%, specificity=68%) and a β-hCG level of ≥1.52 MoM (sensitivity=76%, specificity=70%) acceptably predicted Down syndrome in abnormal amniocentesis cases. Among the 69 abnormal amniocentesis cases, 49 cases had Down syndrome; of these, 75.5% had a Down syndrome risk of ≤1:100.
Conclusion: Both β-hCG and PAPP-A had independent diagnostic value in predicting Down syndrome in early pregnancy. It is recommended that a Down syndrome risk of up to 1:100 warrant direct amniocentesis, while cases with a risk greater than 1:100 should be offered non-invasive alternatives.
Highlights
Maryam Kasraeian (Google Scholar)
Azam Faraji (Google Scholar)
Keywords
- Shiefa S, Amargandhi M, Bhupendra J, Moulali S, Kristine T. First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free beta-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome. Indian J Clin Biochem. 2013;28:3-12. doi: 10.1007/s12291-012-0269-9. PubMed PMID: 24381414; PubMed Central PMCID: PMC3547446.
- Sadlecki P, Walentowicz-Sadlecka M, Pasinska M, Adamczak R, Grabiec M. [Indications for genetic amniocentesis investigated at the Department of Gynecology, Obstetrics, and Oncologic Gynecology, Nicolaus Copernicus University, Collegium Medicum, Bydgoszcz]. Ginekol Pol. 2014;85:420-3. PubMed PMID: 25029805.
- Dey M, Sharma S, Aggarwal S. Prenatal screening methods for aneuploidies. N Am J Med Sci. 2013;5:182-90. doi: 10.4103/1947-2714.109180. PubMed PMID: 23626953; PubMed Central PMCID: PMC3632021.
- Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87:1762-7. doi: 10.1210/jcem.87.4.8430. PubMed PMID: 11932314.
- Carbone L, Cariati F, Sarno L, Conforti A, Bagnulo F, Strina I, et al. Non-Invasive Prenatal Testing: Current Perspectives and Future Challenges. Genes (Basel). 2020;12. doi: 10.3390/genes12010015. PubMed PMID: 33374411; PubMed Central PMCID: PMC7824607.
- Cunningham FG, Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, et al. Williams obstetrics. 24th ed. New York: McGraw-Hill Education; 2014.
- Vafaei H, Hadipour N, Kasraeian M, Yoosefi S, Alamdarloo SM, Asadi N, et al. Accuracy of prenatal ultrasonography for diagnosis of placenta accreta spectrum and risk factors in a tertiary center in southern Iran: one-year placenta accreta in Iran. Galen Med J. 2024;13:e3316. doi: 10.31661/gmj.v13i.3316.
- American College of O, Gynecologists. ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol. 2007;110:1459-67. doi: 10.1097/01.AOG.0000291570.63450.44. PubMed PMID: 18055749.
- Loncar D, Varjacic M, Novakovic T, Milovanovic D, Jankovic S. Correlation between serum biochemical markers and early amniocentesis in diagnosis of congenital fetal anomalies. Bosn J Basic Med Sci. 2010;10:9-14. doi: 10.17305/bjbms.2010.2726. PubMed PMID: 20192924; PubMed Central PMCID: PMC5596620.
- Akbarzadeh-Jahromi M, Todarbary N, Aslani FS, Najib F, Zare M, Amirmoezi F, et al. Uterine smooth muscle tumors of uncertain malignant potential: a retrospective evaluation of clinical pathology and immunohistochemistry features. Surg Exp Pathol. 2024;7:2. doi: 10.1186/s42047-024-00145-5.
- Semati A, Zare M, Mirahmadizadeh A, Hemmati A, Ebrahimi M. Epidemiological Study of Infection and Death Due to COVID-19 in Fars Province, Iran, From February to September 2020. Iran J Med Sci. 2022;47:219-26. doi: 10.30476/IJMS.2021.90768.2174. PubMed PMID: 35634523; PubMed Central PMCID: PMC9126892.
- Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5:1315-6. doi: 10.1097/JTO.0b013e3181ec173d. PubMed PMID: 20736804.
- Faraji A, Gharibpour F, Namazi N, Shakiba AM, Kasraeian M, Asadi N, et al. Foramen Ovale Pulsatility Index as an Early Affected Doppler Study among Abnormal Growth Fetuses: A Recent Insight for Practice Based on a Prospective Study. Iran J Med Sci. 2024;49:632-42. doi: 10.30476/ijms.2024.100177.3231. PubMed PMID: 39449775; PubMed Central PMCID: PMC11497320.
- Delkhosh F, Navinezhad M, Sharifzadeh M, Naghibinasab MS, Eftekhar Yazdi M. Prevalence of aneuploidy in pregnant women with high risk fetal screening in Sabzevar perinatal clinic, 2016–2019. Iran J Obstet Gynecol Infertil. 2022;25:31-8.
- Shahshahan Z. The diagnostic value of combined test for trisomy 21 and 18 screening in over 35-years old pregnant women in the gestational age of 9–14 weeks. J Isfahan Med Sch. 2013;31:400-7. Persian.
- Mirsafaie M, Moghaddam-Banaem L, Kheirollahi M. The Relationship between Screening Markers in the First Trimester of Pregnancy and Chromosome Aberrations. Int J Prev Med. 2022;13:81. doi: 10.4103/ijpvm.IJPVM_572_20. PubMed PMID: 35706851; PubMed Central PMCID: PMC9188895.
- Huang T, Meschino WS, Okun N, Dennis A, Hoffman B, Lepage N, et al. The impact of maternal weight discrepancies on prenatal screening results for Down syndrome. Prenat Diagn. 2013;33:471-6. doi: 10.1002/pd.4090. PubMed PMID: 23512612.
- Ziolkowska K, Dydowicz P, Sobkowski M, Tobola-Wrobel K, Wysocka E, Pietryga M. The clinical usefulness of biochemical (free beta-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy. Ginekol Pol. 2019;90:161-6. doi: 10.5603/GP.2019.0029. PubMed PMID: 30950006.
- Faraji A, Alborzi S, Moradi Alamdarloo S, Kasraeian M, Vafaei H, Asadi N, et al. High level serum inhibin-A in 1st and 2nd pregnancy trimesters as a risk factor for adverse pregnancy outcomes: a systematic review and meta-analysis. Pars J Med Sci. 2022;18:25-34. doi: 10.52547/jmj.18.4.4. Persian.
- Canick JA, Lambert-Messerlian GM, Palomaki GE, Neveux LM, Malone FD, Ball RH, et al. Comparison of serum markers in first-trimester down syndrome screening. Obstet Gynecol. 2006;108:1192-9. doi: 10.1097/01.AOG.0000241095.19638.f2. PubMed PMID: 17077242.
- Kilercik M, Yozgat I, Serdar MA, Aksungar F, Göğüş S, Solak S, et al. What are the predominant parameters for Down syndrome risk estimation in first-trimester screening: a data mining study. Turk J Biochem. 2022;47:704-9. doi: 10.1515/tjb-2022-0004.
- Moreno-Cid M, Rubio-Lorente A, Rodriguez MJ, Bueno-Pacheco G, Tenias JM, Roman-Ortiz C, et al. Systematic review and meta-analysis of performance of second-trimester nasal bone assessment in detection of fetuses with Down syndrome. Ultrasound Obstet Gynecol. 2014;43:247-53. doi: 10.1002/uog.13228. PubMed PMID: 24151178.
- Orlandi F, Bilardo CM, Campogrande M, Krantz D, Hallahan T, Rossi C, et al. Measurement of nasal bone length at 11-14 weeks of pregnancy and its potential role in Down syndrome risk assessment. Ultrasound Obstet Gynecol. 2003;22:36-9. doi: 10.1002/uog.167. PubMed PMID: 12858300.
- Has R, Kalelioglu I, Yuksel A, Ibrahimoglu L, Ermis H, Yildirim A. Fetal nasal bone assessment in first trimester down syndrome screening. Fetal Diagn Ther. 2008;24:61-6. doi: 10.1159/000132409. PubMed PMID: 18504384.
- Patil M, Panchanadikar TM, Wagh G. Variation of papp-a level in the first trimester of pregnancy and its clinical outcome. J Obstet Gynaecol India. 2014;64:116-9. doi: 10.1007/s13224-013-0481-4. PubMed PMID: 24757339; PubMed Central PMCID: PMC3984652.
- Hsu JJ, Ou YC, Chen KC, Hsieh TT, Soong YK. High maternal serum free beta-hCG levels in Down syndrome pregnancies: a preliminary report. Changgeng Yi Xue Za Zhi. 1996;19:36-41. PubMed PMID: 8935373.
- Yaron Y, Ochshorn Y, Tsabari S, Shira AB. First-trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A can detect triploidy and determine the parental origin. Prenat Diagn. 2004;24:445-50. doi: 10.1002/pd.898. PubMed PMID: 15229844.
- Grande M, Jansen FA, Blumenfeld YJ, Fisher A, Odibo AO, Haak MC, et al. Genomic microarray in fetuses with increased nuchal translucency and normal karyotype: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2015;46:650-8. doi: 10.1002/uog.14880. PubMed PMID: 25900824.
)